Now all of a sudden IGF=1 is seen as being a potential side effect.
You are correct Taking external IGF-1 could be a problem espeicially to a person with normal amounts. In the case of bryostatin, PKC epsilon is activating the IGF-1 to be released naturally within the brain. It isn't from an external delivery. The reason why that is important is because Alzheimer's patients have low amounts of the growth factors which is what causes damage to the synapses, so the pkc epsilon is simply increasing something that is deficient.
Market Data 
Markets 
AI
